combining glp-1 receptor agonist with dpp-4 inhibitor not recommended guideline Frontiers Prescribing pearls: A guide to
Description
Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease
This usually resolves as the body adjusts to GLP-1-only activation
(2) major adverse cardiovascular events (MACE)
A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis
Glucagon-like peptide 1 receptor signaling in acinar cells causes growth-dependent release of pancreatic enzymes
